4,480 Shares in Becton, Dickinson and Company $BDX Acquired by Corsicana & Co.

Corsicana & Co. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,480 shares of the medical instruments supplier’s stock, valued at approximately $839,000.

A number of other institutional investors also recently modified their holdings of BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at $26,000. Bell Investment Advisors Inc lifted its stake in shares of Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares in the last quarter. Bank of Jackson Hole Trust grew its holdings in shares of Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $36,000. Finally, CVA Family Office LLC raised its holdings in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 97 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the company. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $205.64.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the sale, the executive vice president owned 13,105 shares in the company, valued at $2,568,973.15. This trade represents a 4.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,036 shares of company stock valued at $197,225 over the last three months. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.5%

BDX stock opened at $195.72 on Friday. The stock has a market cap of $55.86 billion, a P/E ratio of 33.57, a P/E/G ratio of 1.81 and a beta of 0.25. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $189.48 and its two-hundred day simple moving average is $185.45. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.